Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach.

Garcia Vicente AM, Soriano Castrejón A, Amo-Salas M, Lopez Fidalgo JF, Muñoz Sanchez MM, Alvarez Cabellos R, Espinosa Aunion R, Muñoz Madero V.

Rev Esp Med Nucl Imagen Mol. 2016 May-Jun;35(3):152-8. doi: 10.1016/j.remn.2015.08.001. English, Spanish.

PMID:
26522003
2.

Molecular subtypes of breast cancer: metabolic correlation with ¹⁸F-FDG PET/CT.

García Vicente AM, Soriano Castrejón Á, León Martín A, Chacón López-Muñiz I, Muñoz Madero V, Muñoz Sánchez Mdel M, Palomar Muñoz A, Espinosa Aunión R, González Ageitos A.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1304-11. doi: 10.1007/s00259-013-2418-7.

PMID:
23632960
3.

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group..

Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804.

4.

18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.

García Vicente AM, Soriano Castrejón A, Relea Calatayud F, Muñoz Madero V, Molina Garrido MJ, León Martín AA, Cordero García JM, Pilkington Woll JP, Chacón López-Muñiz I, Palomar Muñoz A.

Rev Esp Med Nucl Imagen Mol. 2012 Nov-Dec;31(6):308-14. doi: 10.1016/j.remn.2011.12.001.

5.

Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors.

García Vicente AM, Soriano Castrejón A, Cruz Mora MA, González Ageitos A, Muñoz Sánchez Mdel M, León Martín A, Espinosa Aunión R, Relea Calatayud F, Muñoz Madero V, Chacón López-Muñiz I, Cordero García JM, Jiménez Londoño GA.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(1):72-9. doi: 10.1007/s00259-012-2244-3.

PMID:
23053321
6.

[Subareolar injection: a potential cause of false negative in the selective biopsy of the sentinel node in breast cancer].

Rioja Martín ME, Ortega Pérez G, Cabañas Montero LJ, Muñoz-Madero V, Cabañas Navarro L.

Rev Esp Med Nucl. 2011 Jul-Aug;30(4):251-3. doi: 10.1016/j.remn.2010.07.008. Spanish.

7.

Electrochemotherapy for treatment of skin and soft tissue tumours. Update and definition of its role in multimodal therapy.

Muñoz Madero V, Ortega Pérez G.

Clin Transl Oncol. 2011 Jan;13(1):18-24. doi: 10.1007/s12094-011-0612-2. Review.

PMID:
21239351
8.

[Merkel cell carcinoma in a patient with chronic lymphocytic leukemia].

Cervigón I, Gargallo AB, Bahillo C, Martínez-Amo JL, Orradre JL, Muñoz-Madero V, García-Almagro D.

Actas Dermosifiliogr. 2006 May;97(4):264-6. Spanish.

PMID:
16801021
9.

Possible branchiogenic carcinoma coinciding with metastatic papillary thyroid carcinoma.

Muñoz Madero V, Pérez Sánchez C, Ibáñez D, Puñal Castellanos P, Benito Moreno L.

Eur J Surg Oncol. 1999 Feb;25(1):103-5.

PMID:
10188868

Supplemental Content

Loading ...
Support Center